United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 1 minute read Pharma Industry News Gesynta Pharma reports positive results for GS-248 phase 1 study Swedish pharma company Gesynta Pharma has reported positive results from the phase 1 clinical trial of GS-248, which… bypharmanewsdailyMay 17, 2020
